Similar Posts
Curing Alcoholism with Ketamine Therapy? | Interview with Psychedelic Scientist Dr. Ben Sessa -Awakn
In today’s episode of The Psychedelic Investor, James Hallifax interviews Dr. Ben Sessa of Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a psychedelic medicines company.
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlightFollow us on Instagram:
@thepsychedelicinvestor
@psycspotlightTo learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/Dr. Ben Sessa is the Chief Medical Officer of Awakn and a well-known scientist in the psychedelics field.
In this conversation, Awakn’s newest clinical trial is discussed. The phase 2 trial treated Alcohol Use Disorder using ketamine-assisted therapy, and the results were amazing. For example, by the end of the trial, 86% of participants remained abstinent from alcohol.
From this trial, it is clear that psychedelic therapy, or in this case ketamine therapy, can help with treating addiction. Perhaps the implications of the study go further.
Perhaps, psychedelics can treat mental health issues in general.
Perhaps, ketamine can be used to heal.
In the conversation, MDMA to treat addiction was also discussed.
Interestingly, Dr. Ben Sessa may be the only person in the world who has LEGALLY taken MDMA, psilocybin, LSD and Ketamine.
With mental health care in the spotlight, and we so obviously have a mental health crisis, psychedelic medicines are seeming more likely to be the answer.
From an investment perspective, psychedelic stocks are looking like they could be the next big thing. While there is no guarantee that Awakn will ultimately be a winner, their psychedelic research is definitely a boon for all psychedelic stocks.
#Psychedelics #Awakn #PsychedelicStocks
Is Compass Pathways a GOOD INVESTMENT? (CMPS stock analysis)
In this episode, we take a deep dive into Compass Pathways (CMPS), a psychedelic-medicines company aiming to treat depression with psilocybin.
To understand Compass Pathways (CMPS ), as a company and as an investment, you have to study 5 things:
What problem is Compass Pathways trying to solve?
CMPS’ clinical trial, treating depression with psilocybin
The founders and leaders of Compass Pathways
Compass’ Financials
Is CMPS stock a good investment for a retail investor?As the psychedelic stocks sector takes off, Compass Pathways, alongside MindMed (MMED / MMEDF), looks poised to lead the pack. No other psychedelic-medicines company is as advanced in a clinical trial as is Compass Pathways (CMPS). CMPS has a phase 2b trial to test the effectiveness of psilocybin in treating Treatment-Resistant Depression could be game changing, and make for a great investment opportunity.
Let me know in the comments what you guys think. Is Compass Pathways a GOOD INVESTMENT? Will the CMPS stock skyrocket in 2021?Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.comDISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
Resources:
https://compasspathways.com/https://www.webmd.com/depression/understanding-depression-basics#1
https://www.psychiatry.org/patients-families/depression/what-is-depression
https://www.nimh.nih.gov/health/statistics/major-depression.shtml
https://www.webmd.com/depression/guide/depression-treatment-options#1
https://www.ncbi.nlm.nih.gov/books/NBK361016/#:~:text=Inotherwordsantidepressantsare,foundtobeequallyeffective
https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2222-4#:~:text=Treatmentresistantdepression(TRD),MDDpatientpopulation1
https://www.beckleyfoundation.org/psilocybin-for-depression-2
https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows
https://compasspathways.com/our-research/psilocybin-therapy/about-psilocybin-therapy/#from-subnav
https://psychedelicreview.com/person/ekaterina-malievskaia/
https://compasspathways.com/team-member/george-goldsmith/
https://compasspathways.com/team-member/lars-christian-wilde/https://www.reuters.com/article/us-compass-pathways-ipo/peter-thiel-backed-compass-pathways-files-for-u-s-ipo-idUSKBN25O31T
https://www.globenewswire.com/news-release/2019/05/15/1825506/0/en/Anxiety-Disorder-and-Depression-Treatment-Market-To-Reach-USD-18-90-Billion-By-2026-Reports-And-Data.html
https://www.treehugger.com/facts-about-magic-mushrooms-4868810
https://psychedelicreview.com/person/ekaterina-malievskaia/#CompassPathways #CMPS #PsychedelicStocks #MindMed #MMED #MMEDF #PsychedelicStocks #ThePsychedelicInvestor
This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI & ATAI, CYBIN]
In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Numinus Wellness (NUMI), Cybin.
We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.Timestamps:
0:00 – Intro
0:32 – Norway Decriminalization Bill
1:59 – Psychedelic Market Stats
3:21 – Magic Mushrooms to Treat Obesity
5:40 – Ketamine to Treat Suicidal Thoughts?
7:09 -The Acid King?
8:58 – MindMed (MMED/MMEDF/MMQ) Updates
10:04 – Compass Pathways (CMPS) Updates
11:44 – Atai Life Sciences Updates
14:02 – Numinus (NUMI) Updates
15:13 – CYBIN UpdatesSo this is it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestorFacebook: @thepsychedelicinvestor
Music: www.bensound.comDISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
High Doses, Crystals, and the Dangers of Corporate Takeover with Acacea Lewis
Acacea Lewis shares insights accrued from her extensive experience supporting people doing high dose journey work and integration.
How Long Until Psychedelic Stocks Payoff?🍄🚀| MindMed (MNMD), Cybin (CYBN), Numinus (NUMI) and more
How long until Psychedelic Stocks Payoff?🍄🚀
To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlightFollow us on Instagram:
@thepsychedelicinvestor
@psycspotlightTo learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/While researching a possible investment into psychedelic stocks, you have almost certainly heard the refrain of, “It’s a long-term investment.” I myself, in my many videos for The Psychedelic Investor and articles for PsychedelicSpotlight.com, have probably said this over 100 times.
And while the thesis for investing in psychedelic stocks is appealing, having a timeline clearer than “it’s a long term investment” is necessary before deciding whether it is worth the risk.
In this video, therefore, I endeavor to answer a big question: “When will psychedelic stocks provide a significant return on investment?”
Or, translated to Reddit-speak: when moon?
To start, I feel it’s necessary to give the warning that the answer may be never. To be clear, while I personally believe in the potential for psychedelic stocks such as MindMed (Nasdaq: MNMD, NEO: MMED) and Cybin (NYSE: CYBN, NEO: CYBN), the entire psychedelic medicines industry is inherently speculative and there is no guarantee of success. Yes, the science right now suggests that treatments such as MDMA therapy for PTSD and Ketamine therapy for addiction will disrupt the mental healthcare market, but this needs to be confirmed in larger studies.
There will be two separate turning points for psychedelic medicines and the companies that produce them: the legalization of the first psychedelic medicines, and the legalization of improved next-generation psychedelics.
The first will happen relatively soon.
#PsychedelicStocks #MindMed #Cybin
Top 5 Catalysts for Psychedelic Stocks In The Second Half of 2021 (MNMD,CMPS,ATAI,TRYP, CYBN & MORE)
What are top 5 catalysts for psychedelic stocks in the second half of 2021? Stay tuned to hear how stocks like MindMed (NASDAQ: MNMD),
(NEO:MMED), Compass Pathways (NASDAQ: CMPS), atai Life Sciences ( NASDAQ: ATAI), Tryp Therapeutics, Cybin and more will affect the psychedelic industry in 2021.Timestamps:
0:00 – Intro
1:38 – #5: A New Psychedelics ETF (PSIL)
4:57 – #4:California Decriminalizing possession of psychedelics, and Legalising the personal production of Psilocybin
7:30 – #3:The commencement of MANY phase 2a trials
10:16 – #2: MindMed’s Project Lucy phase 2b trial begins
11:47 – #1: Compass Pathways phase 2b trial results releasedEnjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestorWant to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.comCheck out our website: thepsychedelicinvestor.com
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor#MindMed #MNMD #PsychedelicStocks
![This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI & ATAI, CYBIN]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-46-600x338.jpeg)
